Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $12000.0.

  • Lineage Cell Therapeutics' Capital Expenditures fell 8928.57% to $12000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $488000.0, marking a year-over-year increase of 6769.76%. This contributed to the annual value of $565000.0 for FY2024, which is 1617.21% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Capital Expenditures stood at $12000.0 for Q3 2025, which was down 8928.57% from $14000.0 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Capital Expenditures ranged from a high of $365000.0 in Q4 2024 and a low of -$16000.0 during Q4 2022
  • For the 5-year period, Lineage Cell Therapeutics' Capital Expenditures averaged around $111315.8, with its median value being $97000.0 (2022).
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 205000.0% in 2021, then tumbled by 11095.89% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Capital Expenditures stood at $146000.0 in 2021, then plummeted by 110.96% to -$16000.0 in 2022, then surged by 668.75% to $91000.0 in 2023, then soared by 301.1% to $365000.0 in 2024, then crashed by 96.71% to $12000.0 in 2025.
  • Its Capital Expenditures stands at $12000.0 for Q3 2025, versus $14000.0 for Q2 2025 and $97000.0 for Q1 2025.